

## キーワード索引

### 第78巻 平成20年

## A

a submucosal tumor .....(1) 18  
 ablation .....(12) 538  
 abnormal muscle tonus .....(Ex) E26  
 accelerometric recordings .....(Ex) E26  
 acetylcholine receptor .....(Ex) E178  
 action potential .....(1) 61  
 acute ischemic stroke .....(Ex) E119, E124, E160  
 acute stroke .....(Ex) E149  
 adiponectin .....(10・11) 461  
 adrenocortical adenoma .....(7) 285  
 adrenocortical carcinoma .....(7) 285  
 adults .....(12) 544  
 adult Leigh's disease .....(Ex) E75  
 aesthetic medicine .....(2・3) 135  
 after cardiac transplantation .....(7) 316  
 aging .....(2・3) 125  
 Alzheimer disease .....(Ex) E134  
 amyotrophic lateral sclerosis .....(Ex) E19  
 anaphylactoid purpura .....(Ex) E191  
 ANCA-associated glomerulonephritis .....(7) 310  
 anesthetic management .....(7) 316  
 angiotensin II .....(5) 218  
 angiotensin II type I receptor blocker  
 (ARB) .....(Ex) E119  
 angiotensin IV .....(5) 218  
 angulation error .....(Ex) E109  
 anti-aging .....(2・3) 135  
 anti-mitochondrial antibody .....(4) 198  
 anti-PF4/heparin antibody .....(12) 525  
 anti-VGKC antibody .....(Ex) E105  
 antibacterial agents .....(6) 266  
 antioxidant therapy .....(Ex) E194  
 Antiphospholipid syndrome .....(1) 1  
 aortic root .....(12) 513  
 apoptosis .....(1) 10  
 apperceptive visual agnosia .....(Ex) E134  
 aquaporin .....(Ex) E42  
 aquaporin-4 .....(Ex) E94  
 arterial hypertension .....(Ex) E119  
 arthroscopic synovectomy .....(2・3) 111  
 aspirin .....(Ex) E10  
 atherosclerosis .....(Ex) 154, (10・11) 461  
 attributable risk percent .....(2・3) 95  
 autonomic dysfunction .....(Ex) E99  
 autopsy .....(12) 554

## B

$\beta$ -2glycoprotein I .....(1) 1  
 basic fibroblast growth factor .....(8・9) 448  
 Bicêtre hospital .....(Ex) E140  
 blink reflex .....(1) 35  
 bioethics .....(12) 549  
 bone metabolism .....(6) 260  
 brain damage .....(8・9) 454  
 brain magnetic resonance angiography .....(Ex) E149  
 breast cancer .....(4) 189

## C

c-maf .....(1) 10  
 $Ca^{2+}$  oscillation-inducing sperm factor .....(1) 61  
 Candidiasis .....(1) 47  
 CAPD .....(6) 266  
 capnography .....(2・3) 103  
 cardiac surgery .....(12) 525  
 cardiomegaly .....(10・11) 479  
 cardiopulmonary bypass(CPB) .....(10・11) 474  
 carotid artery .....(Ex) E154  
 carotid artery ultrasonography .....(Ex) E149  
 carotid stenosis .....(2・3) 77  
 carotid ultrasonography .....(2・3) 77  
 cauda equina .....(Ex) E57  
 cenesthopathy .....(Ex) E203  
 cerebellar infarction .....(Ex) E163  
 cerebral ischemia .....(Ex) E67  
 cerebral vasculitis .....(Ex) E191  
 cerebrovascular disease .....(2・3) 95, (4) 177,  
 (Ex) E53  
 cholangitis .....(2・3) 85  
 chromosome 7 .....(Ex) E109  
 Chronic hepatitis C .....(7) 306  
 chronic hepatitis .....(2・3) 85  
 chronic pancreatitis .....(1) 55  
 cilostazol .....(Ex) E83  
 cirrhosis .....(2・3) 85  
 clinical guideline .....(Ex) E169  
 clinical practice .....(Ex) E61  
 coagulation-fibrinolysis markers .....(Ex) E124  
 collagen disease .....(4) 198  
 communication .....(1) 30  
 computed tomography .....(10・11) 474  
 computed tomography(CT) .....(8・9) 454

conduite d'approche.....(Ex)E198  
 continued nutrition education program .....(2·3) 119  
 copying .....(Ex)E109  
 corrected TGA .....(12) 538  
 CSF tap test .....(Ex)E169  
 CT staging .....(6) 275

**D**

dermatological changes .....(2·3) 125  
 Dermatomycosis .....(1) 47  
 Dermatophytosis.....(1) 47  
 Devic's disease .....(Ex)E42  
 diabetes.....(6) 266  
 diabetic nephropathy .....(5) 213, 218  
 diagnosis .....(Ex)E163  
 dizziness .....(Ex)E70  
 dopa-responsive dystonia.....(Ex)E186  
 dopamine agonist .....(Ex)E182  
 double J stent .....(6) 275  
 Double-Switch .....(12) 538  
 dry skin .....(2·3) 132

**E**

early hepatocellular carcinoma.....(1) 6  
 echocardiography .....(6) 280  
 ectopic hormone-producing tumor .....(7) 285  
 ED ratio .....(Ex)E149  
 edrophonium test .....(Ex)E173  
 egg cell physiology .....(1) 61  
 electroencephalogram(EEG) .....(8·9) 454  
 electrophysiological study .....(Ex)E173  
 emphysematous pyelonephritis .....(6) 275  
 encephalopathy .....(8·9) 454  
 endocarditis .....(12) 513  
 endocrine cell carcinoma .....(1) 18  
 endocrine dysfunction .....(12) 519  
 endometrial carcinoma.....(8·9) 431  
 endometrial hyperplasia .....(8·9) 431  
 endoscopic hemostasis .....(8·9) 448  
 endoscopic pancreatocholangiography .....(1) 55  
 endoscopic retrograde  
   cholangiopancreatography .....(1) 55  
 endoscopic sphincterotomy .....(1) 55  
 endothelial cell .....(Ex)E83  
 epidemiology .....(4) 177, (6) 253  
 epilepsy.....(1) 35  
 etCO<sub>2</sub> .....(2·3) 103  
 ex-vivo renal surgery .....(1) 23  
 extremely-low-birth-weight infants .....(12) 549

**F**

facial genu .....(Ex) E6  
 facial paralysis .....(Ex) E6  
 factor Xa inhibitor .....(Ex) E10  
 female hormones .....(2·3) 125  
 female researcher .....(8·9) 443  
 fibrin glue .....(8·9) 448  
 fixation of the bar .....(12) 544  
 fluent aphasia .....(Ex)E198  
 Fontan operation .....(12) 531  
 foot ulcer .....(6) 270  
 France .....(Ex)E140  
 functional pathology .....(6) 239  
 funding .....(8·9) 443  
 fungal peritonitis .....(6) 266

**G**

gastrectomy .....(Ex)E182  
 gastric cancer .....(1) 18, (2·3) 119  
 gestational trophoblastic disease .....(5) 230  
 Gleason grade & score .....(4) 182  
 glomerulonephritis .....(5) 213  
 Goethe .....(12) 554  
 Graves' disease .....(7) 306, (10·11) 468  
 guideline .....(2·3) 77

**H**

*h*-index .....(8·9) 443  
 headaches.....(12) 519  
 heart physiology .....(10·11) 474  
 hemodialysis .....(7) 310, (10·11) 461  
 hemorrhagic gastric ulcer .....(8·9) 448  
 heparin-induced thrombocytopenia .....(12) 525  
 hepatocellular nodules .....(1) 6  
 HER2.....(4) 189  
 high altitude .....(Ex)E53  
 HIV-infection .....(Ex)E105  
 Ho: YAG laser .....(2·3) 111  
 hormone replacement therapy .....(2·3) 125  
 human relation.....(1) 30  
 hyperkinetic motor behaviour .....(Ex)E67  
 hyperlalia .....(Ex)E67  
 hypoxia .....(Ex)E53  
 hypoxic training .....(Ex)E53

**I**

- idiopathic normal pressure  
 hydrocephalus .....(Ex)E169  
 imaging and postoperative care .....(10·11) 474  
 immunoadsorption plasma pheresis .....(Ex) E94  
 immunohistochemistry .....(4) 182  
 infective endocarditis .....(7) 313  
 inflammation .....(Ex)E154  
 inflammatory myofibroblastic tumor .....(5) 225  
 infliximab .....(6) 260  
 intercellular lipid of stratum corneum .....(2·3) 132  
 Interferon  $\alpha$  .....(7) 306  
 internal carotid artery stenosis .....(Ex)E149  
 international normalized ratio .....(Ex)E129  
 intra-articular injections .....(2·3) 90  
 intracellular  $\text{Ca}^{2+}$  .....(1) 61  
 invasive mole .....(5) 230  
 involuntary movements .....(Ex) E26  
 iodine diet .....(10·11) 468  
 Isaacs' syndrome .....(Ex)E105  
 ischemic preconditioning .....(Ex) E53  
 ischemic stroke .....(2·3) 77  
 ischemic-reperfusion renal injury .....(1) 10

**K**

- KAKENHI .....(8·9) 443  
 kidney cancer .....(1) 23  
 kidney preserving surgery .....(1) 23  
 kidney transplantation .....(1) 23

**L**

- L-DOPA .....(Ex)E182  
 large cell lung cancer .....(6) 280  
 lateral reticular formation .....(1) 35  
 leg dystonia .....(Ex)E186  
 levodopa .....(Ex)E186  
 lower motor neuron .....(Ex) E6  
 lung cancer .....(6) 253  
 lupus nephritis .....(5) 213

**M**

- magnetic resonance imaging .....(5) 225, 230, (6) 280  
*Malassezia* infection .....(1) 47  
 mammalian fertilization .....(1) 61  
 medical economics .....(4) 177  
 medical research .....(7) 300  
 medical statistics .....(7) 300

- medical studies .....(8·9) 437  
 medical treatment .....(1) 30  
 meningoencephalitis .....(Ex)E191  
 menopause .....(2·3) 125  
 mesangial cell .....(5) 218  
 metastatic cardiac involvement .....(6) 280  
 metastatic lymph nodes .....(4) 189  
 MG .....(Ex)E173  
 microbubble .....(Ex)E160  
 midbrain .....(Ex)E75  
 mitochondria .....(Ex)E75  
 morphology .....(12) 554  
 motor neuron disease .....(Ex)E19  
 multiple sclerosis .....(Ex) E42, E75  
 muscarinic acetylcholine receptor .....(Ex)E178  
 muscle cramp .....(Ex)E105  
 Myasthenia Gravis .....(Ex)E178  
 myocardial biopsy .....(Ex)E75  
 myocardial hypertrophy .....(10·11) 479

**N**

- narrative based medicine(NBM) .....(1) 30  
 necrotizing vasculitis .....(Ex)E191  
 negative .....(Ex)E178  
 nerve conduction study .....(Ex)E57  
 neuroblastoma .....(7) 285  
 neurology .....(Ex)E140  
 neuromyelitis optica .....(Ex) E42, E94  
 neuromyotonia .....(Ex)E105  
 neuronal reorganization .....(Ex)E67  
 NMO IgG .....(Ex)E94  
 NMO-IgG .....(Ex)E42  
 non-ablative .....(2·3) 135  
 non-intubated .....(2·3) 103  
 non-invasive .....(2·3) 135  
 non-specific reaction .....(4) 198  
 normal endometrium .....(8·9) 431  
 NTx .....(6) 260

**O**

- Onychomycosis .....(1) 47  
 optic nerve .....(Ex)E61  
 oral breathing .....(2·3) 103  
 organic life theory .....(12) 554  
 orthostatic hypotension .....(Ex)E70  
 osteoarthritis .....(2·3) 90  
 oxidative stress .....(1) 10  
 oxidizes low density lipoprotein .....(Ex)E145

## P

palmar sweating ..... (Ex) E88  
 pancreaticobiliary maljunction ..... (1) 55  
 papillary thyroid carcinoma ..... (6) 239  
 Parkinson's disease ..... (Ex) E182, E203  
 Parkinson disease ..... (Ex) E88  
 parkinsonism ..... (Ex) E182  
 pathology ..... (10·11) 479  
 pathology of the liver ..... (2·3) 85  
 pectus excavatum ..... (12) 544  
 percutaneous electrical stimulation ..... (Ex) E57  
 perinatal medicine ..... (12) 549  
 phenotype ..... (Ex) E19  
 pheochromocytoma ..... (7) 285  
 phonemic paraphasias ..... (Ex) E198  
 phosphodiesterase inhibitor ..... (Ex) E10  
 primary biliary cirrhosis(PBC) ..... (4) 198  
 pituitary adenoma ..... (6) 239  
 plaque instability ..... (Ex) E154  
 plasminogen activator inhibitor-1 ..... (5) 218  
 platelet activation ..... (Ex) E83  
 platelet aggregation ..... (Ex) E145  
 plethysmography ..... (Ex) E70  
 Pneumocystis carinii pneumonia ..... (7) 310  
 polymorphism ..... (1) 1  
 pregnancy ..... (Ex) E94  
 prevention ..... (2·3) 95  
 primary biliary cirrhosis(PBC) ..... (4) 198  
 primary hyperparathyroidism ..... (6) 239  
 prognosis ..... (Ex) E169  
 prostate cancer ..... (4) 182  
 psoas abscess ..... (6) 270  
 pulse wave velocity ..... (10·11) 461

## Q

QOL ..... (2·3) 142  
 quality of life ..... (2·3) 119

## R

radiculopathy ..... (Ex) E57  
 radioiodine therapy ..... (10·11) 468  
 Rathke's cleft cyst ..... (12) 519  
 recipient twin ..... (10·11) 479  
 rectal cancer surgery ..... (7) 313  
 reductive medicine ..... (12) 554  
 Rehabili-make® ..... (2·3) 142  
 rejuvenation ..... (2·3) 135, 142  
 renal biopsy ..... (5) 213

renal cell carcinoma ..... (4) 182  
 renal stone ..... (6) 275  
 renal vascular surgery ..... (1) 23  
 reoperation ..... (12) 513  
 rheumatoid arthritis ..... (2·3) 90, 111  
 rheumatoid arthritis(RA) ..... (6) 260  
 risk factor ..... (Ex) E124  
 risk factors ..... (Ex) E163

## S

S-100 $\beta$  protein ..... (8·9) 454  
 sarcoid neuropathy ..... (Ex) E99  
 sarcoidosis ..... (Ex) E99  
 Schellong test ..... (Ex) E70  
 sedation ..... (2·3) 103  
 seizure ..... (Ex) E191  
 selegiline ..... (Ex) E194  
 senile freckle ..... (2·3) 132  
 sensori-motor multiple mononeuropathies ..... (Ex) E99  
 seroconversion ..... (12) 525  
 shear-induced platelet aggregation ..... (Ex) E145  
 sicca syndrome ..... (Ex) E99  
 single-photon emission computed tomography  
 (SPECT) ..... (Ex) E203  
 Skindex-16 ..... (2·3) 142  
 slowly progressive aphasia ..... (Ex) E198  
 smoking ..... (6) 253  
 sodium hyaluronate ..... (2·3) 90  
 softening of the anterior chest wall ..... (12) 544  
 spastic paraparesis ..... (Ex) E186  
 SPECT ..... (Ex) E67  
 statistical analysis ..... (8·9) 437  
 statistical consultation ..... (7) 300  
 steatohepatitis ..... (2·3) 85  
 steroids ..... (2·3) 90  
 stroke in young adults ..... (1) 1  
 stroke prevention ..... (Ex) E129  
 submuscular modified Nuss procedure ..... (12) 544  
 subtype classification ..... (Ex) E163  
 superficial siderosis ..... (Ex) E194  
 supraventricular tachycardia ..... (12) 538  
 surface electromyogram ..... (Ex) E26

## T

the dorsal pathway ..... (Ex) E134  
 the ventral pathway ..... (Ex) E134  
 thermoregulatory sweating ..... (Ex) E88  
 thienopyridine ..... (Ex) E10  
 thrombin inhibitor ..... (Ex) E10  
 thyroid carcinomas ..... (6) 239

time trend.....( 6 ) 253  
 tissue factor .....(Ex)E154  
 tissue plasminogen activator(t-PA).....(Ex)E160  
 tobacco control .....( 6 ) 253  
 total cavo-pulmonary connection(TCPC)  
   conversion .....(12) 531  
 total globulin .....(12) 525  
 transcranial Doppler.....(Ex)E160  
 transplantation .....( 5 ) 213  
 transsphenoidal surgery .....(12) 519  
 trastuzumab.....( 4 ) 189  
 tricuspid valve.....( 7 ) 313  
 trophoblastic disease .....(8·9) 431  
 tumor necrosis factor-alpha(TNF- $\alpha$ ).....( 6 ) 260  
 twin-to-twin transfusion syndrome  
   (TTTS) .....(10·11) 479  
 type 2 diabetes.....( 6 ) 270

## U

ultrasound .....(Ex)E160  
 ultraviolet light .....(2·3) 132  
 unique *E. coli* buffer .....( 4 ) 198  
 upper motor neuron .....(Ex) E6  
 urinary iodine excretion .....(10·11) 468  
 urothelial carcinoma .....( 4 ) 182  
 uterus .....( 5 ) 225, 230

## V

vagus nerve stimulation.....( 1 ) 35  
 vascular territory .....(Ex)E163  
 visual attention .....(Ex)E134  
 visual evoked potential .....(Ex) E61  
 visual hallucination .....(Ex)E203  
 visual impairment .....(12) 519  
 visual processing .....(Ex) E61  
 visuospatial disability .....(Ex)E109  
 voiding dysfunction .....(Ex)E178

## W

Warfarin .....(Ex)E129  
 warm-heartedness .....(12) 549  
 well-aging .....(2·3) 142  
 Williams syndrome .....(Ex)E109  
 wound healing .....(8·9) 448  
 wrinkle .....(2·3) 132

## Y

years of potential life lost .....(2·3) 95  
 Yokukansan .....(Ex)E203